0.0000 (0.0000%)
  • Bid / Lots
    1.8800/ 1
  • Ask / Lots
    1.9600/ 56
  • Open / Previous Close
    1.9900 / 1.9250
  • Day Range
    Low 1.8701
    High 1.9900
  • 52 Week Range
    Low 0.9000
    High 7.9600
  • Volume
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Wednesday's close: 1.87
09:32 ET1621.99
09:33 ET61321.89
09:35 ET1001.8701
09:37 ET10801.9709
09:39 ET6001.9
09:44 ET4001.9
09:50 ET1001.88
09:55 ET1001.915
10:26 ET2001.88
10:44 ET1001.88
10:56 ET2501.88
11:00 ET10491.91
11:07 ET3131.935
11:20 ET1001.9599
12:03 ET1001.9101
12:10 ET25711.91
12:12 ET1001.91
12:51 ET1001.91
01:06 ET1001.92
01:45 ET21001.91
01:47 ET2001.91
01:49 ET2001.91
01:56 ET9001.9499
02:14 ET1001.9101
02:25 ET1401.92
03:14 ET2001.925
03:44 ET1001.925
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesADAG
Adagene Inc
United StatesCRIS
Curis Inc
United StatesAMAM
Ambrx Biopharma Inc
United StatesSLS
Sellas Life Sciences Group Inc
United StatesCGEN
Compugen Ltd
United StatesADVM
Adverum Biotechnologies Inc
As of 2023-01-27

Company Information

Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. The Company is principally engaged in the research, development and production of monoclonal antibody drugs for cancers. The Company’s main products include: ADG106 is being developed for the treatment of advanced solid tumors and non-Hodgkin's lymphoma, or NHL. ADG126 is designed to address the toxicity and efficacy issues related to the MOA of existing approved CTLA-4 immuno-oncology therapies and to expand the potential of CTLA-4 as a target for the treatment of cancer. ADG116 is designed to target a unique conserved epitope of CTLA-4. And ADG104, a monospecific antibody that targets PD-L1 and is in Phase Ib and Phase II clinical trials concurrently in China.

Contact Information

4F, Building C14, No. 218 Xinghu Street, Suzhou Industrial ParkSUZHOU, JNG, China 215123


Chairman of the Board, Chief Executive Officer, Co-Founder
Peter Luo
Chief Financial Officer, Director
Tam Man Kin
Executive Vice President of Clinical Development
Zha Jiping
Senior Vice President of Global Regulatory Affairs
Shang Jin
Senior Vice President, Head of Clinical Operations
She Xiaohong

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
Revenue (TTM)
Shares Outstanding
Dividend Yield
Annual Dividend Rate
Ex-Dividend Date
Pay Date
Book Value
P/E Ratio
Price/Sales (TTM)
Price/Cash Flow (TTM)
Operating Margin
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.